G1T38: Experimental Treatment for Estrogen Receptor-Positive, HER2-negative (ER+, HER2-) Breast Cancer

Scientific rationale and therapeutic potential

G1T38 is a potent and selective oral CDK4/6 inhibitor designed to block the proliferation of breast-cancer cells and induce tumor-cell death when combined with a selective estrogen receptor degrader (SERD, such as Faslodex®). G1T38 has the potential to be best-in-class versus other oral CDK4/6 inhibitors.

Preclinical and clinical results (see: Publications)

G1 is currently recruiting patients for a Phase 1b/2a trial of G1T38 in ER+, HER2- breast cancer

G1T38-02 Study  
  • ER+, HER2- breast cancer, after endocrine therapy failure
  • Multi-center, randomized, open-label
  • G1T38 + Faslodex┬«
  • Approximately 80 patients
  • ClinicalTrials.gov Identifier: NCT02983071


For additional information on the trials, please visit: G1CancerTrials.com

Click here for printable version of our G1T38 ER+ HER2- breast cancer clinical trial fact sheet